2018年1月
Metabolic activity by F-18-FDG-PET/CT is predictive of early response after nivolumab in previously treated NSCLC
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING
- 巻
- 45
- 号
- 1
- 開始ページ
- 56
- 終了ページ
- 66
- 記述言語
- 英語
- 掲載種別
- 研究論文(学術雑誌)
- DOI
- 10.1007/s00259-017-3806-1
- 出版者・発行元
- SPRINGER
Nivolumab, an anti-programmed death-1 (PD-1) antibody, is administered in patients with previously treated non-small cell lung cancer. However, little is known about the established biomarker predicting the efficacy of nivolumab. Here, we conducted a preliminary study to investigate whether F-18-FDG-PET/CT could predict the therapeutic response of nivolumab at the early phase.
Twenty-four patients were enrolled in this study. F-18-FDG-PET/CT was carried out before and 1 month after nivolumab therapy. SUVmax, metabolic tumour volume (MTV), and total lesion glycolysis (TLG) were calculated. Immunohistochemical analysis of PD-L1 expression and tumour-infiltrating lymphocytes was conducted.
Among all patients, a partial metabolic response to nivolumab was observed in 29% on SUVmax, 25% on MTV, and 33% on TLG, whereas seven (29%) patients achieved a partial response (PR) based on RECIST v1.1. The predictive probability of PR (100% vs. 29%, p = 0.021) and progressive disease (100% vs. 22.2%, p = 0.002) at 1 month after nivolumab initiation was significantly higher in F-18-FDG on PET/CT than in CT scans. Multivariate analysis confirmed that F-18-FDG uptake after administration of nivolumab was an independent prognostic factor. PD-L1 expression and nivolumab plasma concentration could not precisely predict the early therapeutic efficacy of nivolumab.
Metabolic response by F-18-FDG was effective in predicting efficacy and survival at 1 month after nivolumab treatment.
Twenty-four patients were enrolled in this study. F-18-FDG-PET/CT was carried out before and 1 month after nivolumab therapy. SUVmax, metabolic tumour volume (MTV), and total lesion glycolysis (TLG) were calculated. Immunohistochemical analysis of PD-L1 expression and tumour-infiltrating lymphocytes was conducted.
Among all patients, a partial metabolic response to nivolumab was observed in 29% on SUVmax, 25% on MTV, and 33% on TLG, whereas seven (29%) patients achieved a partial response (PR) based on RECIST v1.1. The predictive probability of PR (100% vs. 29%, p = 0.021) and progressive disease (100% vs. 22.2%, p = 0.002) at 1 month after nivolumab initiation was significantly higher in F-18-FDG on PET/CT than in CT scans. Multivariate analysis confirmed that F-18-FDG uptake after administration of nivolumab was an independent prognostic factor. PD-L1 expression and nivolumab plasma concentration could not precisely predict the early therapeutic efficacy of nivolumab.
Metabolic response by F-18-FDG was effective in predicting efficacy and survival at 1 month after nivolumab treatment.
- リンク情報
- ID情報
-
- DOI : 10.1007/s00259-017-3806-1
- ISSN : 1619-7070
- eISSN : 1619-7089
- PubMed ID : 28828507
- Web of Science ID : WOS:000416151400008